CN1698741A - Gingko leaf slow-releasing tablet and preparation process thereof - Google Patents
Gingko leaf slow-releasing tablet and preparation process thereof Download PDFInfo
- Publication number
- CN1698741A CN1698741A CNA2005100434887A CN200510043488A CN1698741A CN 1698741 A CN1698741 A CN 1698741A CN A2005100434887 A CNA2005100434887 A CN A2005100434887A CN 200510043488 A CN200510043488 A CN 200510043488A CN 1698741 A CN1698741 A CN 1698741A
- Authority
- CN
- China
- Prior art keywords
- parts
- gingko leaf
- slow
- leaf slow
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a gingko leaf slow-releasing tablet and preparation process, wherein the slow release tablet is prepared from (by weight ratio) the following raw materials, ginkgo leaf extract 120 parts, at least one kind of pharmaceutically acceptable surface active agent 5-50 parts, at least one kind of pharmaceutically acceptable hydrophilic gel matrix material 20-80 parts, at least one kind of pharmaceutically acceptable excipient 50-400 parts. The preparing process comprises mixing the ginkgo leaf extract with the surface active agent homogeneously, then mixing with hydrophilic gel polymers and other excipient homogeneously, directly tabletting or preparing granules then tabletting.
Description
Technical field
The present invention belongs to field of pharmaceutical preparations, specifically, relates to a kind of gingko leaf slow-releasing table and preparation method thereof.
Technical background
Semen Ginkgo just does medicinal since time immemorial in China, be mainly used in the beneficial heart and astringe the lung, and the pain relieving of relievining asthma is used for lung-heat, cough, coronary heart disease, angina pectoris.Folium Ginkgo is the leaf of Ginkgoaceae plant Ginkgo biloba, has another name called Folium Ginkgo.According to " Treatise on Dietetic Therapy " record, Folium Ginkgo can be used for diseases such as severe palpitation, cough and asthma due to lung deficiency.1960's, West Germany has promptly begun the research of Folium Ginkgo.They find; in the Folium Ginkgo based on the effective ingredient of flavone; have the effect of protection capillary permeability, coronary artery dilator, recovery arteries elasticity, nourishing brain cell and other organ, and the peculiar effect that makes blood matter in tremulous pulse, peripheral vessel, the blood capillary and cholesterol keep normal level in addition.Find that bilobalide is strong platelet activating factor PAF antagonist the beginning of the nineties, might be used to allosome repulsion that prevents and treats respiratory tract anaphylaxis disease (particularly asthma), thrombosis, some inflammation, ulcer, shock, organ transplantation etc.At present both at home and abroad the research of Semen Ginkgo is mainly concentrated in the development and use of ginkgetin in the Folium Ginkgo extract and bilobalide.According to pharmacology and clinical research in the past, ginkgetin has expansion of cerebral vascular, reduces cerebral vascular resistance, reduces capillary permeability, and the cerebral blood flow increasing amount is removed the free radical effect.Bilobalide is a platelet activating factor antagonist, can reduce blood viscosity, improves blood flowing characteristic.Bilobalide and flavone have better therapeutic effect for the treatment heart, cerebrovascular disease.About the existing a lot of reports of the extracting method of bilobalide and ginkgetin.German Willmar scgwabe pharmaceutical factory proposed ginkgo leaf standard extract (EGB) in the German patent DE 3940092 of its application in 1991, by being generally acknowledged the international market.The main apricot yellow ketone of argentiferous 〉=24%, Quercetin and kaempferol peak are than between the 0.8-1.5; Ginkgo total lactones 〉=6%; Ginkgoic acid＜10ppm.
Having developed and be used for clinical ginkgo leaf extract preparation both at home and abroad has tablet, and capsule, injection, drop, oral liquid, pill and ointment etc. are ordinary preparation.As conventional tablet, the every apricot yellow ketone 9.6mg of argentiferous, oral 1 time 1～2, three times on the 1st.Dosing interval is shorter, and the effective blood drug concentration fluctuation is bigger.As the curative of cardiovascular and cerebrovascular disease, need take for a long time, many in order to solve administration number of times, the technical barrier that blood concentration fluctuation is big, Chinese patent literature CN1177603C disclose a kind of technical scheme of gingko leaf slow-releasing table.It is characterized in that the tablet made with the following weight proportion raw material: 120 parts of Folium Ginkgo extract, 80～100 parts of hydroxypropyl emthylcelluloses, 50～80 parts of lactose, 30～80 parts of starch, 2～5 parts of magnesium stearate, 0.8～1.2 part of dehydrated alcohol.The preparation method of gingko leaf slow-releasing table is: it is made up of the following step: 1) produce Folium Ginkgo extract, 2) make slow releasing tablet: with Folium Ginkgo extract, hydroxypropyl emthylcellulose, lactose and starch mix homogeneously, adding dehydrated alcohol again granulates, add magnesium stearate mixing tabletting then, last coating is promptly made gingko leaf slow-releasing table.This technical scheme is unexposed to reach for what kind of slow release effect.People such as Lv Hong have introduced a kind of employing ginkgo liquid dry extract 10g, ethyl cellulose 2g, Pulvis Talci 3g, the gingko leaf slow-releasing table of full pressed powder (referring to Lv Hong etc., the preparation of gingko leaf slow-releasing table and external release kinetics, Wuhan Institute of Chemical Technology's journal 2000,22 (1): 7～9) this slow releasing tablet ginkgetin discharged for zero level at 2～12 hours.Liu Qingfei etc. to the stability of Ginkgo total lactones controlled release piller carried out studying (referring to Liu Qingfei etc., 349～352), but the prescription of unexposed controlled release piller and preparation technology the stability study of Ginkgo total lactones controlled release piller, Chinese patent medicine 2004,26 (5):.
Known ginkgetin is hydrophilic, and bilobalide is lipophilic, and the two plays synergism in vivo, because the two qualitative difference, the slow releasing preparation with the routine techniques preparation often causes the asynchronous of release in vitro, influences interior curative effect.Prior art is inappropriate to ginkgetin or the control of only bilobalide being carried out drug release behavior only.
Summary of the invention
In order to solve above-mentioned technical barrier, provide a kind of gingko leaf slow-releasing table that can control ginkgetin and bilobalide synchronous slow.
Another object of the present invention is to provide the preparation method of above-mentioned slow releasing tablet.
Gingko leaf slow-releasing table of the present invention, with two appendix XD first methods of Chinese Pharmacopoeia version in 2000, adopt dissolution method first subtraction unit, with water 500ml is release medium, rotating speed is that per minute 100 changes when measuring, and all should be respectively more than 15%～50% and 65% at 2 hours and 12 hours Ginkgo total flavones and the burst size of Folium Ginkgo terpene lactones.
Gingko leaf slow-releasing table of the present invention, make by following materials of weight proportions:
120 parts of Folium Ginkgo extract
5～50 parts at least a pharmaceutically acceptable surfactant
20～80 parts of at least a pharmaceutically acceptable hydrophilic gel framework materials
50～400 parts of at least a pharmaceutically acceptable excipient.
Described surfactant is selected from one or more in pharmaceutically acceptable ionic surfactant and/or the nonionic surfactant.Ionic surfactant preferably sodium dodecyl sulfate wherein.The preferred Tweens of nonionic surfactant, spans, wheat pool class, poloxalkol class etc., most preferably Tween 80, poloxamer 188.
Described hydrophilic gel framework material is selected from one or more of hypromellose, Carboxymethyl cellulose sodium, hydroxyethyl-cellulose, hydroxypropyl cellulose, methylcellulose, sodium carboxymethyl cellulose, tragacanth, chitin, galactomannan, sodium alginate, potassium alginate, polyvinyl alcohol, carbomer.Preferred viscosity ranges is the hypromellose of 100mPa.s～15000mPa.s, and promptly methoxyl content is 19～24% weight, and the hydroxyl hydroxypropoxyl content is the hypromellose of 4～12% weight.Can be by the viscosity of selecting hydroxypropyl methylcellulose and the slow release degree that consumption is regulated required preparation.
Described pharmaceutically acceptable excipient is meant pharmaceutically acceptable filler, lubricant etc.Described filler and lubricant are conventional adjuvant pharmaceutically.
The preparation method of ginkgo biloba extract sustained-release sheet of the present invention be with Folium Ginkgo extract and surfactant mix homogeneously, again with hydrophilic gel polymer and other excipient mixings, direct compression or make granule after tabletting.
Folium Ginkgo extract of the present invention, the main apricot yellow ketone of argentiferous 〉=24%, Quercetin and kaempferol peak are than between the 0.8-1.5; Ginkgo total lactones 〉=6%; Ginkgoic acid＜10ppm.
Ginkgo biloba extract sustained-release sheet of the present invention can be controlled the release of Ginkgo total flavones, Folium Ginkgo terpene lactones simultaneously, with two appendix XD first methods of Chinese Pharmacopoeia version in 2000, adopt dissolution method first subtraction unit, with water 500ml is release medium, rotating speed is that per minute 100 changes when measuring, and all should be respectively more than 15%～50% and 65% at 2 hours and 12 hours Ginkgo total flavones and the burst size of Folium Ginkgo terpene lactones.Gingko leaf slow-releasing table of the present invention can be controlled the synchronous release of Ginkgo total flavones, Folium Ginkgo terpene lactones, is used for clinical treatment and has the advantage that administration number of times is few, blood concentration fluctuation is little.
It is simple that preparation method of the present invention has technology, is suitable for suitability for industrialized production.
The specific embodiment
Below will the invention will be further described by embodiment, these descriptions are not that content of the present invention is done further to limit.One skilled in the art will understand that to be equal to replacement to what content of the present invention was done, or corresponding the improvement, still belong within protection scope of the present invention.
Embodiment 1:
The composition weight proportion
120 parts of Folium Ginkgo extract
15 parts of sodium lauryl sulphates
25 parts of poloxamers
55 parts of hypromelloses (K4M CR)
85 parts of lactose
80 parts of microcrystalline Cellulose
20 parts of micropowder silica gels
6 parts of magnesium stearate
Preparation technology:
With Folium Ginkgo extract and sodium lauryl sulphate, poloxamer mix homogeneously, again with lactose, microcrystalline Cellulose, hypromellose mix homogeneously, add magnesium stearate, micropowder silica gel then, mixing, direct compression of full-powder.
The release in vitro degree is checked: get this product, according to drug release determination method (two appendix XD first methods of Chinese Pharmacopoeia version in 2000), adopt dissolution method first subtraction unit, with water 500ml is release medium, and rotating speed is that per minute 100 changes, operation in accordance with the law, respectively at 2,6,12 hours take a sample successively 50ml, 40ml, 40ml (and instant water that in stripping rotor, replenishes equal volume, uniform temp), filter, get subsequent filtrate, as need testing solution.
The release of total flavones is got 10 of this product in addition, and accurate the title decides, and porphyrize is got about 0.5 amount, the accurate title, decide, and puts in the 250ml measuring bottle, adds 70% ethanol to scale, shakes up, put in 37 ℃ of water-baths supersound process 30 minutes, and shook up, filter, get subsequent filtrate solution in contrast with microporous filter membrane; Precision is measured above-mentioned contrast solution and each 2.0ml of need testing solution, put respectively in the 10ml measuring bottle, add water to 3ml, add acetic acid-sodium-acetate buffer 2ml of pH4.5, the aluminum trichloride solution 2ml of 0.1mol/L, add 70% ethanol dilution to scale, shaking up, is blank with the reagent corresponding, according to spectrophotography (appendix VB of Chinese Pharmacopoeia version in 2000) test, wavelength place at 270nm measures trap, calculates every burst size at different time as follows respectively.
Burst size=[(test liquid trap ÷ sample average sheet is heavy)/(contrast liquid trap ÷ control sample sample weighting amount)] * 2 * 100%
The release of terpene lactone
The preparation precision of need testing solution is measured 2h, 6h, 12h subsequent filtrate 40ml, 30ml, 25ml, be evaporated to dried, residue adds the 20ml ethyl acetate, put reflux 1h in the water-bath (90 ℃), take out, filter, filter and residue wash with an amount of ethyl acetate, merging filtrate and washing liquid, the sodium acetate solution 10ml washing with 5% divides and gets sodium acetate solution, wash with ethyl acetate 10ml, merge ethyl acetate liquid, reclaim ethyl acetate to doing, the residue precision adds mobile phase 5ml makes abundant dissolving, shake up, microporous filter membrane with 0.45 μ m filters, and gets subsequent filtrate, as need testing solution.
It is an amount of that bilobalide, ginkalide A, ginkalide B, ginkalide C reference substance are got in the preparation of reference substance solution respectively, accurately claims surely, adds mobile phase and make the mixed solution that every 1ml contains 1mg, 0.5mg, 0.5mg, 0.5mg, promptly gets reference substance solution A; It is an amount of that precision is measured reference substance solution A, adds mobile phase and be diluted to the reference substance solution that every 1ml contains 0.5mg, 0.25mg, 0.25mg, 0.25mg, promptly gets reference substance solution B.Precision is measured each 1ml of reference substance solution A, B under the assay item, puts respectively in the 10ml measuring bottle, adds mobile phase and is diluted to scale, shakes up, in contrast product solution C, D.
Accurate respectively reference substance solution C, D and each the 200 μ l of need testing solution of drawing of algoscopy, inject chromatograph of liquid, measure, calculate the burst size of bilobalide, ginkalide A, ginkalide B, ginkalide C respectively with external standard two-point method logarithmic equation, and calculate the burst size of total lactone.
The cumulative release degree of present embodiment is as follows:
| Time (hour) | The cumulative release degree (%) of total flavones | The cumulative release degree (%) of terpene lactones |
| ?2 | ?25.2 | ?34.2 |
| ?6 | ?53.4 | ?56.3 |
| ?12 | ?89.1 | ?92.0 |
Embodiment 2:
The composition weight proportion
120 parts of Folium Ginkgo extract
15 parts of Tween 80s
25 parts of hypromelloses (K15M CR)
100 parts of lactose
100 parts of microcrystalline Cellulose
20 parts of micropowder silica gels
6 parts of magnesium stearate
Preparation technology:
Behind Folium Ginkgo extract and the Tween 80 mix homogeneously, add other adjuvants, mixing, tabletting.
Release in vitro degree inspection method is with embodiment 1.
Present embodiment cumulative release degree is as follows:
| Time (hour) | The cumulative release degree (%) of total flavones | The cumulative release degree (%) of terpene lactones |
| 2 | ?23.1 | ?31.5 |
| 6 | ?47.2 | ?50.2 |
| 12 | ?85.0 | ?84.9 |
Embodiment 3:
The composition weight proportion
120 parts of Folium Ginkgo extract
5 parts of docusate sodium
5 parts of Tween 80s
35 parts of hypromelloses (K4M)
10 parts of hypromelloses (K15M)
125 parts of lactose
130 parts of microcrystalline Cellulose
20 parts of micropowder silica gels
6 parts of magnesium stearate
Preparation technology is with embodiment 2, and release in vitro degree inspection method is with embodiment 1.
Present embodiment cumulative release degree is as follows:
| Time (hour) | The cumulative release degree (%) of total flavones | The cumulative release degree (%) of terpene lactones |
| ?2 | ?21.0 | ?28.3 |
| ?6 | ?40.6 | ?45.6 |
| ?12 | ?90.1 | ?88.3 |
Embodiment 4:
The composition weight proportion
120 parts of Folium Ginkgo extract
15 parts of sodium lauryl sulphates
30 parts of poloxamers
20 parts of hypromelloses (K100LV)
50 parts of hypromelloses (K4M)
100 parts of lactose
100 parts of microcrystalline Cellulose
20 parts of micropowder silica gels
6 parts of magnesium stearate
Preparation technology and release in vitro degree inspection method are with embodiment 1.
Present embodiment cumulative release degree is as follows:
| Time (hour) | The cumulative release degree (%) of total flavones | The cumulative release degree (%) of terpene lactones |
| ?2 | ?35.6 | ?41.2 |
| ?6 | ?62.3 | ?65.3 |
| ?12 | ?95.6 | ?96.8 |
Embodiment 5:
The composition weight proportion
120 parts of Folium Ginkgo extract
15 parts of sodium lauryl sulphates
30 parts of poloxamers
30 parts of hypromelloses (K100LV)
15 parts of hypromelloses (K15M)
120 parts of lactose
120 parts of microcrystalline Cellulose
20 parts of micropowder silica gels
6 parts of magnesium stearate
Preparation technology and release in vitro degree inspection method are with embodiment 1.
Present embodiment cumulative release degree is as follows:
| Time (hour) | The cumulative release degree (%) of total flavones | The cumulative release degree (%) of terpene lactones |
| ?2 | ?35.2 | ?39.4 |
| ?6 | ?67.1 | ?62.8 |
| ?12 | ?96.3 | ?90.3 |
Embodiment 6:
The composition weight proportion
120 parts of Folium Ginkgo extract
15 parts of sodium lauryl sulphates
30 parts of poloxamers
50 parts of hypromelloses (viscosity is 10000mPa.s)
105 parts of lactose
110 parts of microcrystalline Cellulose
20 parts of micropowder silica gels
6 parts of magnesium stearate
Preparation technology and release in vitro degree inspection method are with embodiment 1.
Present embodiment cumulative release degree is as follows:
| Time (hour) | The cumulative release degree (%) of total flavones | The cumulative release degree (%) of terpene lactones |
| ?2 | ?23.2 | ?27.3 |
| ?6 | ?47.8 | ?45.0 |
| ?12 | ?83.3 | ?80.0 |
Embodiment 7:
The composition weight proportion
120 parts of Folium Ginkgo extract
15 parts of sodium lauryl sulphates
30 parts of poloxamers
10 parts of chitosan
25 parts of sodium alginates
85 parts of lactose
85 parts of microcrystalline Cellulose
20 parts of micropowder silica gels
6 parts of magnesium stearate
Preparation technology and release in vitro degree inspection method are with embodiment 1.
Present embodiment cumulative release degree is as follows:
| Time (hour) | The cumulative release degree (%) of total flavones | The cumulative release degree (%) of terpene lactones |
| ?2 | ?23.9 | ?32.7 |
| ?6 | ?67.1 | ?65.6 |
| ?12 | ?91.3 | ?88.2 |
Embodiment 8:
The composition weight proportion
120 parts of Folium Ginkgo extract
15 parts of sodium lauryl sulphates
30 parts of poloxamers
25 parts of hypromelloses (K4M)
50 parts of carbomers (934P)
100 parts of lactose
100 parts of microcrystalline Cellulose
20 parts of micropowder silica gels
6 parts of magnesium stearate
Preparation technology and release in vitro degree inspection method are with embodiment 1.
Present embodiment cumulative release degree is as follows:
| Time (hour) | The cumulative release degree (%) of total flavones | The cumulative release degree (%) of terpene lactones |
| ?2 | ?29.5 | ?33.1 |
| ?6 | ?55.7 | ?59.9 |
| ?12 | ?86.6 | ?81.7 |
Claims (8)
1. gingko leaf slow-releasing table, it is characterized in that: with two appendix XD first methods of Chinese Pharmacopoeia version in 2000, adopt dissolution method first subtraction unit, with water 500ml is release medium, rotating speed is that per minute 100 changes when measuring, and is more than 15%～50% and 65% respectively at 2 hours and 12 hours Ginkgo total flavones and the burst size of Folium Ginkgo terpene lactones.
2. according to the gingko leaf slow-releasing table of claim 1, it is characterized in that, is to be made by the raw material of following weight portion:
120 parts of Folium Ginkgo extract
5～50 parts at least a pharmaceutically acceptable surfactant
20～80 parts of at least a pharmaceutically acceptable hydrophilic gel framework materials
50～400 parts of at least a pharmaceutically acceptable excipient.
3. according to the gingko leaf slow-releasing table of claim 2, it is characterized in that: described surfactant is one or more in ionic surfactant and/or the nonionic surfactant.
4. gingko leaf slow-releasing table according to claim 3 is characterized in that: described ionic surfactant is a sodium lauryl sulphate; Described nonionic surfactant is Tweens, spans, wheat pool class or poloxalkol class.
5. gingko leaf slow-releasing table according to claim 4 is characterized in that: described nonionic surfactant is Tween 80 or poloxamer 188.
6. according to the gingko leaf slow-releasing table of claim 2, it is characterized in that: described hydrophilic gel framework material is one or more of hypromellose, Carboxymethyl cellulose sodium, hydroxyethyl-cellulose, hydroxypropyl cellulose, methylcellulose, sodium carboxymethyl cellulose, tragacanth, chitin, galactomannan, sodium alginate, potassium alginate, polyvinyl alcohol, carbomer.
7. gingko leaf slow-releasing table according to claim 6 is characterized in that: described hydrophilic gel framework material is that range of viscosities is the hypromellose of 100mPa.s～15000mPa.s.
8. the preparation method of each described gingko leaf slow-releasing table of claim 1-7, it is characterized in that: with Folium Ginkgo extract and surfactant mix homogeneously, again with hydrophilic gel polymer and other excipient mixings, direct compression or make granule after tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100434887A CN100341522C (en) | 2005-05-16 | 2005-05-16 | Gingko leaf slow-releasing tablet and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100434887A CN100341522C (en) | 2005-05-16 | 2005-05-16 | Gingko leaf slow-releasing tablet and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1698741A true CN1698741A (en) | 2005-11-23 |
| CN100341522C CN100341522C (en) | 2007-10-10 |
Family
ID=35475094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100434887A Active CN100341522C (en) | 2005-05-16 | 2005-05-16 | Gingko leaf slow-releasing tablet and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100341522C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744786B (en) * | 2008-12-17 | 2012-11-14 | 南京星银药业集团有限公司 | Prescription of felodipine sustained-release tablets and preparation method |
| CN103429230A (en) * | 2011-04-27 | 2013-12-04 | 威玛舒培博士两合公司 | Controlled release tablet of ginkgo biloba extract and procedure for obtaining it |
| CN103599140A (en) * | 2013-11-18 | 2014-02-26 | 沈阳药科大学 | Bilobalide controlled release tablet and preparation method thereof |
| CN104224860A (en) * | 2014-10-13 | 2014-12-24 | 北京人福军威医药技术开发有限公司 | Ginkgo leaf sustained-release tablet with stable release performance |
| KR101612762B1 (en) * | 2014-11-04 | 2016-04-15 | 에스케이케미칼 주식회사 | Pharmaceutical composition comprising Ginkgo biloba extract and matrix of sustained release hydrophilic polymers, and its oral sustained release formulation |
| WO2017146286A1 (en) * | 2016-02-26 | 2017-08-31 | 에스케이케미칼주식회사 | Pharmaceutical composition of ginkgo biloba leaf extract using matrix of sustained-release hydrophilic polymer, and sustained-release oral preparation using same |
| KR20170115332A (en) * | 2016-04-07 | 2017-10-17 | 에스케이케미칼주식회사 | Sustained-release pharmaceutical compositions containing ginkgo biloba extracts |
| KR20170115384A (en) * | 2016-04-07 | 2017-10-17 | 에스케이케미칼주식회사 | Sustained-release pharmaceutical compositions containing ginkgo biloba extracts |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH704253A1 (en) * | 2010-12-21 | 2012-06-29 | Mepha Gmbh | Pharmaceutical composition containing herbal ingredients. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177603C (en) * | 2002-03-22 | 2004-12-01 | 山西亚宝药业集团股份有限公司 | Gingko leaf slow-releasing table and preparation process thereof |
-
2005
- 2005-05-16 CN CNB2005100434887A patent/CN100341522C/en active Active
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744786B (en) * | 2008-12-17 | 2012-11-14 | 南京星银药业集团有限公司 | Prescription of felodipine sustained-release tablets and preparation method |
| CN103429230A (en) * | 2011-04-27 | 2013-12-04 | 威玛舒培博士两合公司 | Controlled release tablet of ginkgo biloba extract and procedure for obtaining it |
| CN103599140A (en) * | 2013-11-18 | 2014-02-26 | 沈阳药科大学 | Bilobalide controlled release tablet and preparation method thereof |
| CN103599140B (en) * | 2013-11-18 | 2016-03-02 | 沈阳药科大学 | Bilobalide controlled release tablet and preparation method |
| CN104224860A (en) * | 2014-10-13 | 2014-12-24 | 北京人福军威医药技术开发有限公司 | Ginkgo leaf sustained-release tablet with stable release performance |
| KR101612762B1 (en) * | 2014-11-04 | 2016-04-15 | 에스케이케미칼 주식회사 | Pharmaceutical composition comprising Ginkgo biloba extract and matrix of sustained release hydrophilic polymers, and its oral sustained release formulation |
| WO2017146286A1 (en) * | 2016-02-26 | 2017-08-31 | 에스케이케미칼주식회사 | Pharmaceutical composition of ginkgo biloba leaf extract using matrix of sustained-release hydrophilic polymer, and sustained-release oral preparation using same |
| KR20170115332A (en) * | 2016-04-07 | 2017-10-17 | 에스케이케미칼주식회사 | Sustained-release pharmaceutical compositions containing ginkgo biloba extracts |
| KR20170115384A (en) * | 2016-04-07 | 2017-10-17 | 에스케이케미칼주식회사 | Sustained-release pharmaceutical compositions containing ginkgo biloba extracts |
| KR102539236B1 (en) * | 2016-04-07 | 2023-06-02 | 에스케이케미칼 주식회사 | Sustained-release pharmaceutical compositions containing ginkgo biloba extracts |
| KR102539234B1 (en) * | 2016-04-07 | 2023-06-02 | 에스케이케미칼 주식회사 | Sustained-release pharmaceutical compositions containing ginkgo biloba extracts |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100341522C (en) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100341522C (en) | Gingko leaf slow-releasing tablet and preparation process thereof | |
| CN1946426A (en) | Sustained release formulation for oral administration of HMG-CoA reductase inhibitor and method for the preparation thereof | |
| CN1939305A (en) | Cephalofruxin ester liposome, its preparation and medicinal composition containing it | |
| CN106511348B (en) | Huperzine skeleton particle, oral disintegrating tablet and preparation method thereof | |
| CN1586475A (en) | Vitamin C oral disintegration tablet and its preparing method | |
| CN1911209A (en) | Quick-disintegration tablets of calcium atovastatine, and its prepn. method | |
| CN1813860A (en) | Naoxinqing Chinese medicine dispersible tablet and its preparing process | |
| CN1823802A (en) | Gastrodin slow release preparation | |
| CN1608621A (en) | Fine bicyclic alcohol powder and oral bicyclic alcohol release controlling prepn | |
| CN1965817A (en) | Sustained release tablet of glibenclamide and preparation process thereof | |
| CN1927301A (en) | Tongmai Jiangzhi dispersant tablet and method for making same | |
| CN1853634A (en) | Composition comprising itraconazole for oral administration | |
| CN1241568C (en) | Compound paracetamol and chlorphenamine maleate slow releasing tablet and its preparation | |
| CN1543971A (en) | Oral disintegrating tablet and its preparation of compound red sage root | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
| CN1891256A (en) | Red sage root dispersible tablet for treating cornary heart diseae and its preparing method | |
| CN1895250A (en) | Gliquilone slow-releasing preparation | |
| CN1273116C (en) | Orally disintegrating tablet of gingko leaf and its preparation process | |
| CN1839835A (en) | Lacidipine pharmaceutical formulation preparing method | |
| CN1298318C (en) | Sodium ferulic acid osmosis pump controlled release formulation and its preparation method | |
| CN1589782A (en) | Dimethyl biguanidine hydrochloride slow release particle and its preparation method | |
| CN100336506C (en) | Orally disintegrating tablet of phentolamine mesylate and its preparation method | |
| CN1682730A (en) | Cepharanthine slow releasing preparation | |
| CN1209109C (en) | Slow-releasing acipimox tablet | |
| CN1634014A (en) | Sodium ferulate oral disintegrating tablet and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BAINUO MEDICINES DEVELOPMENT CO., LTD., JINAN Free format text: FORMER OWNER: JINAN HUANUO MEDICINE TECHNOLOGY CO., LTD. Effective date: 20150529 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250013 JINAN, SHANDONG PROVINCE TO: 250000 JINAN, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150529 Address after: 250000 Ji'nan, Shandong hi tech Zone, East China Road century wealth center C block, 201 Patentee after: Bainuo Medicines Development Co., Ltd., Jinan Address before: 250013, No. 69, Pioneer Road, Huayang Road, Licheng District, Shandong, Ji'nan 325 Patentee before: Jinan Huanuo Medicine Technology Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 250000 Ji'nan, Shandong hi tech Zone, East China Road century wealth center C block, 201 Patentee after: SHANDONG BESTCOMM PHARMACEUTICAL CO., LTD. Address before: 250000 Ji'nan, Shandong hi tech Zone, East China Road century wealth center C block, 201 Patentee before: Bainuo Medicines Development Co., Ltd., Jinan |